Farmaprojects | Polpharma Group

The future of pharma growth will be built through partnerships. At Farmaprojects | Polpharma Group, we believe the best innovations are built together. As a leading pan-European pharmaceutical player, with a consolidated footprint and a well-established leadership position in CEE, Polpharma Group combines deep pharmaceutical expertise, world-class development and manufacturing capabilities, and a long-term commitment to global collaboration. As part of our Strategic Partnerships initiative, we're actively seeking collaboration opportunities in: ✅ Hard-to-make Rx ✅ Complex injectables ✅ US-focused partnerships ✅ Co-development opportunities that accelerate access to new pipeline and markets Our goal is simple: combine synergies to bring differentiated medicines to patients faster. If this resonates with your objectives, reach out to Bernardo Reiner, Ana Patrícia Freitas Rei or Jorge Espírito Santo

CPHI Milan made one thing clear: partners are looking for an integrated path from oligonucleotide API to finished product. We’re ready to deliver. Three intense days of meaningful conversations about partners’ needs and how we can move their projects forward as Europe’s No. 1 integrated oligonucleotide platform. Made in the EU. Built for today and beyond 2040. Strong interest in our respiratory portfolio opened further opportunities to help partners bring medicines to patients. Thank you to everyone who met with us and to the Polpharma Group and Polpharma API | CDMO teams. Your next project. Our shared commitment. Let’s make it happen, together.

All in on oligonucleotides. Today and beyond 2040. 🧬 Recorded at CPHI Milan, where we talked with partners about the opportunities ahead and how we can move their next oligonucleotide project forward. At Farmaprojects | Polpharma Group, we’re building on a clear strategy: • 12 oligonucleotide assets in a strong and growing portfolio. • A vertically integrated platform, from API to finished product. • Made in the EU, supporting quality and reliable supply. • A roadmap to 2040 and beyond. Through licensing, co-development and supply partnerships, we’re ready to grow together. Have a project in mind? Let’s talk.

Your next growth opportunity in Oligonucleotides starts here. Access a vertically integrated, EU-made platform—from API to finished product—with licensing, co-development and supply partnerships built for today and beyond 2040. Your partner? Farmaprojects | Polpharma Group. Europe’s No. 1 integrated partner for oligonucleotides. Bring your idea. Let’s move your next project forward, together. Discover the opportunities with Bernardo Reiner and Hendrik M. 📍 Let’s talk at CPHI Milan, stand 7A50.

Yes, we have open positions! We are looking for a Corporate Lawyer to join our team. Working at Farmaprojects means joining a Great Place To Work Spain. It means joining #OneTeam, focused on making things happen. We are an agile team with the power of a European market leader Polpharma Group. That combination gives you: the agility to move fast and the scale to aim high. In this role, you will work closely with different teams across the business, providing practical legal guidance on corporate, commercial and compliance matters, managing contracts and helping the business grow while navigating legal requirements. ✅ Apply here: https://lnkd.in/eiD4hihS

Peptides are far behind injectable formulations and a limited number of indications. Today, the market, pipeline, and technology tell a much broader story. Five signals confirm this: 1. Steady market growth The global peptide therapeutics market is set to reach $49.7B in 2026 and exceed $70B by 2031 (CAGR 7.2%). 2. A diversifying opportunity Oncology led in 2025 (35.5% share), but gastrointestinal disorders are the fastest-growing area (CAGR 11.9%), and rare diseases topped peptide approvals from 2014–2024. 3. A pipeline beyond GLP-1s 150+ peptide drugs approved worldwide, with 71 candidates in Phase III — spanning metabolic (34%), oncology, cardiovascular, CNS, musculoskeletal, hormonal, and GI conditions. 4. Route of administration as an innovation frontier Parenteral still leads (80.6% of volume), but oral formulations are growing at 12.9% CAGR. 5. Evolving production technology Solid-phase synthesis still dominates (45.1%), but recombinant expression is growing fastest (CAGR 13.7%). Their next stage of growth depends not only on new molecules, but on the industry's ability to formulate, deliver, and manufacture them efficiently at scale. At Farmaprojects | Polpharma Group, we are ready. Peptides are part of our strategic vision. If you are looking for a reliable partner in the peptide space, contact us. We want to shape the future of B2B together with you. ✨